Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents (Q33695784)

28 July 2017

1 reference

title

Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents (English)

1 reference

28 July 2017

Doherty AM

1

1 reference

28 July 2017

1 August 1999

1 reference

Current Opinion in Chemical Biology

28 July 2017

1 reference

28 July 2017

3

1 reference

28 July 2017

4

1 reference

28 July 2017

466-473

1 reference

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

28 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

The cDNA of a human lymphocyte cyclic-AMP phosphodiesterase (PDE IV) reveals a multigene family

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Isolation of a cDNA encoding a human rolipram-sensitive cyclic AMP phosphodiesterase (PDE IVD)

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Molecular cloning and expression of a human phosphodiesterase 4C.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Cyclic nucleotide phosphodiesterase 4 subtypes are differentially expressed by primary keratinocytes and human epidermoid cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Characterization of the rolipram-sensitive, cyclic AMP-specific phosphodiesterases: identification and differential expression of immunologically distinct forms in the rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Subcellular localization of rolipram-sensitive, cAMP-specific phosphodiesterases. Differential targeting and activation of the splicing variants derived from the PDE4D gene

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Expression and regulation of mRNA for distinct isoforms of cAMP-specific PDE-4 in mitogen-stimulated and leukemic human lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and Gs-coupled receptor agonists. Potential role in beta2-adrenoreceptor desensitization.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

A selective type 4 phosphodiesterase inhibitor, T-440, modulates intracellular cyclic AMP level and interleukin-2 production of Jurkat cells

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Regulation of interleukin-13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergen-specific human T lymphocyte clones

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Inhibition of eotaxin-mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Role of cyclic adenosine monophosphate in reducing superoxide anion generation in guinea pig alveolar macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Theophylline-induced mesenteric periarteritis in F344/N rats

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by three selective type-4 phosphodiesterase inhibitors: in vitro and in vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Enhancement of motility and acrosome reaction in human spermatozoa: differential activation by type-specific phosphodiesterase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Effect of pregnancy on PDE4 cAMP-specific phosphodiesterase messenger ribonucleic acid expression in human myometrium

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Oocyte maturation involves compartmentalization and opposing changes of cAMP levels in follicular somatic and germ cells: studies using selective phosphodiesterase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Drug treatment of asthma in the 1990s: achievements and new strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Effect of T-440, a novel type IV phosphodiesterase inhibitor, on allergen-induced immediate and late asthmatic reaction and leukocyte infiltration into the airways of guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Anti-inflammatory and bronchodilator properties of KF19514, a phosphodiesterase 4 and 1 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Prevention of ozone-induced airway hyperresponsiveness and epithelial injury by phosphodiesterase inhibitors in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Chronic obstructive pulmonary disease: new opportunities for drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Delayed treatment with rolipram protects against neuronal damage following global ischemia in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Protection against blood-brain barrier disruption in focal cerebral ischemia by the type IV phosphodiesterase inhibitor BBB022: a quantitative study.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

The type IV phosphodiesterase inhibitors, Ro 20-1724 and rolipram, block the initiation of cocaine self-administration.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Rolipram, an antidepressant that increases the availability of cAMP, transiently enhances wakefulness in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Reduced DNA synthesis and cell viability in small cell lung carcinoma by treatment with cyclic AMP phosphodiesterase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2899%2980068-4

7 January 2021

10.1016/S1367-5931(99)80068-4

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10419856